I don't know and cannot contribute much to what others have posted. Think that a truly ultra rapid-acting insulin coming from Novo or Lilly could well compete with current fast-acting market but I do have doubts about the 2 unpartnered programs from BIOD and HALO plus if Novo does not expect these tweaks to be highly consequential, they should know better than me. Going to meet next month with a small local bio that is going in this direction just with a different solution (other than tweaking insulin analogs), so perhaps I'll learn something new.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.